DRKS00022785Active, not recruitingNot Applicable
Beating Heart Mitral Valve REPair With the HARPOON™ System: ReaL World Outcomes From a multICenter observATional European Registry - REPLICATE
Harpoon Medical, an indirect wholly-owned subsidiary of Edwards Lifesciences Corporation, Edwards Lifesciences0 sites26 target enrollmentStarted: October 5, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 26
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •Subjects who are clinically suitable for treatment with the HARPOON™ System, as per the Instructions for Use (IFU), will be evaluated for inclusion in the registry.
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Not Applicable
Stentless mitral valve replacement using autologous pericardium studyMitral regurgitationJPRN-UMIN000012659Sakakibara Heart Institute25
Completed
Not Applicable
Stentless mitral valve replacement using autologous pericardium studyMitral valve diseaseJPRN-UMIN000021445Keio University School of Medicine30
Suspended
Not Applicable
Stentless mitral valve replacement using autologous pericardium studyMitral regurgitationJPRN-jRCT1032180087Shimokawa Tomoki25
Completed
Not Applicable
Tiara* Transcatheter Mitral Valve Replacement Studysevere mitral regurgitation10046973NL-OMON49193eovasc Medical Inc.30
Completed
Not Applicable
Mitral valve surgery using stentress bioprosthesis made from autologous pericardiumMitral insufficiencyJPRN-UMIN000017201CV suregry5